Stock Detail
INSMED INC
Diversified Services
INSM @ Yahoo Finance | INSM Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $3.01 | $3.07 | $0.02 | 0.67% | 0.00 | $2.99 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $2.97 | $2.93 | 81,768 | 74.75M | 179,728.33 | -0.97 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 3.14 | 3.07 | 3.00 | 2.93 | 2.86 |
Stock Profile
Insmed Incorporated, a biopharmaceutical company, engages in the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders. Its lead product includes recombinant human insulin-like growth factor-I bound to recombinant human insulin-like growth factor binding protein-3 (rhIGF-I/rhIGFBP-3), a Phase III clinical trial product, which would be used for the treatment of severe growth disturbance due to growth hormone insensitivity syndrome. The company's research and development stage products include rhIGFBP-3, for the treatment of various cancers; and INSM-18, for the treatment of various tumors. The company has strategic relationships with Fujisawa Pharmaceutical Co., Ltd.; Tzamal Pharmaceutical; Pharmacia, Inc.; and Avecia Limited. Insmed was incorporated in 1999 and is based in Glen Allen, Virginia.